Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 11/20 | 0.74 |
| ▸ | ACP1 | P24666 | 7/20 | 0.74 |
| ▸ | AKR1B1 | P15121 | 7/20 | 0.70 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.60 |
| ▸ | PTPRF | P10586 | 1/20 | 0.60 |
| ▸ | PTPRB | P23467 | 1/20 | 0.60 |
| ▸ | MMP3 | P08254 | 1/20 | 0.59 |
| ▸ | MMP13 | P45452 | 1/20 | 0.59 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5460575 | 1.00 | PTPN1 (0.74) | PTPN1ACP1AKR1B1PTPN2PTPRF | |
| SCHEMBL5460010 | 0.91 | PTPN1 (0.72) | PTPN1ACP1AKR1B1PTPN2PTPRF | |
| SCHEMBL5460018 | 0.91 | PTPN1 (0.72) | PTPN1ACP1AKR1B1PTPN2PTPRF | |
| SCHEMBL5457238 | 0.83 | PTPN1 (0.72) | PTPN1ACP1AKR1B1PTPN2PTPRF | |
| SCHEMBL5457241 | 0.83 | PTPN1 (0.72) | PTPN1ACP1AKR1B1PTPN2PTPRF | |
| SCHEMBL5462289 | 0.83 | PTPN1 (0.66) | PTPN1ACP1AKR1B1PTPN2 | |
| SCHEMBL5462282 | 0.83 | PTPN1 (0.66) | PTPN1ACP1AKR1B1PTPN2 | |
| SCHEMBL5457373 | 0.82 | PTPN1 (0.67) | PTPN1ACP1AKR1B1PTPN2PTPRF | |
| SCHEMBL5465160 | 0.82 | PTPN1 (0.67) | PTPN1ACP1AKR1B1PTPN2PTPRF | |
| SCHEMBL5462864 | 0.81 | MEN1 (0.62) | PTPN1ACP1AKR1B1PTPN2PTPRF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070276011-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276011-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | SERPINE1, SERPINC1, SERPINB1 | PTPN1 3264/4885ACP1 254/4885AKR1B1 1236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.